TOKYOMEDIJAPAN MEDICAL REFERENCE
⌕ Search databaseOfficial source · PMDA / MHLW
Rx · Reference only · no online purchase

Enhertu (Trastuzumab deruxtecan)

Enhertu / Trastuzumab deruxtecan. Used for selected breast, stomach, lung and other solid cancers meeting specific HER2 criteria.

PMDAproduct-level source2026-09label updated2026-10-05site verified
エンハーツ点滴静注用100mg · 100 mg
Japanese product photo · 100 mg · 日刊工業新聞
Main useUsed for selected breast, stomach, lung and other solid cancers meeting specific HER2 criteria.A brief overview of Japanese approved uses. Check the PMDA label below for product-specific conditions.
Japan product name
エンハーツ点滴静注用100mg
Brand
Enhertu
Generic name
Trastuzumab deruxtecan
Japanese generic name
トラスツズマブ デルクステカン
Chinese name
曲妥珠单抗德鲁斯特康
Marketing authorization holder
第一三共株式会社
Strengths
100 mg
Dosage form
IV infusion
Therapeutic area
Oncology
Regulatory status
Rx
Label updated
2026-09
TOKYO MEDI verified
2026-10-05
MEDICINE REFERENCE

Detailed product reference

Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.

01

Product overview

Enhertu is a HER2-directed antibody–drug conjugate, distinct from trastuzumab alone and T-DM1.

Read source section ↗
02

Mechanism of action

Delivers a topoisomerase-I inhibitor into HER2-expressing cells. HER2 expression and mutation are different tests.

Read source section ↗
03

Japanese indications & eligibility

Japanese indications cover selected HER2-defined breast, lung, gastric and other solid cancers under treatment-history conditions.

Read source section ↗
04

Administration & dose differences

Label doses are generally 5.4 mg/kg every three weeks, or 6.4 mg/kg for gastric cancer; some breast regimens combine pertuzumab.

Read source section ↗
05

Adverse effects & key risks

Major concerns include potentially fatal interstitial lung disease, myelosuppression, nausea and cardiac dysfunction.

Read source section ↗
06

Contraindications & special populations

Ingredient hypersensitivity is contraindicated. Assess lung/cardiac disease, liver function and reproductive risks.

Read source section ↗
07

Drug interactions

Check combination drugs and follow product-specific preparation, dilution and infusion requirements.

Read source section ↗
08

Assessment & monitoring

Monitor lung symptoms/imaging, blood counts, liver function and left ventricular function.

Read source section ↗
09

Storage & handling

Unopened vials require 2–8°C refrigeration; preparation and storage after reconstitution follow the label.

Read source section ↗
10

Sources & verification

Product checked ·

Official source

These links go directly to PMDA records for this Japanese product. Professional and patient-facing sources are separated.